(1 - 10 from 11
)
Oncology Data Advisor - Moxetumomab Pasudotox-Tdfk for ...
oncdata.com
· Robert Kreitman, MD. Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response
UT Southwestern Ricin Researchers Chafe at Security Crackdown -...
www.redorbit.com
Researchers at UT Southwestern Medical Center in Dallas have spent years and millions of dollars building vaccines and cancer treatments with ricin, a toxin so...
AstraZeneca wins FDA OK for leukemia drug | BioPharma Dive
www.biopharmadive.com
... their first treatment," said Robert Kreitman, head of clinical immunotherapy section, Center for Cancer Research, National Cancer Institute, ...
sorted by relevance / date